People · Operator
Named in public records as an officer, director or promoter · active 2009–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| BioAegis Therapeutics, Inc. | — | Biotechnology | Series B | $42.4M | $457.8M | 2012 |
| Critical Biologics Corp | — | Biotechnology | Pre-Seed | $500K | $27.6M | 2009 |
Thomas Stossel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas Stossel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gerald Chan | 1 | 13 |
| James W. Fordyce | 1 | 4 |
| Valerie Ceva | 1 | 2 |
| Susan Levinson | 1 | 2 |
| Steven L. Cordovano | 1 | 1 |
| Steve Cordovano | 1 | 1 |
| Steven Cordovano | 1 | 1 |
| Mark DiNubile | 1 | 1 |
| John Stossel | 1 | 1 |
| Scott Coleridge | 1 | 1 |
| Ashleigh W. Palmer | 1 | 1 |
| Susan L. Levinson | 1 | 1 |
| Valerie L. Ceva | 1 | 1 |
| Thomas L. Stossel | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.